<DOC>
	<DOC>NCT02614898</DOC>
	<brief_summary>This is a prospective, open-label study with no patient randomization. Treatment for atypical hemolytic uremic syndrome (aHUS) will remain observational and at the discretion of the treating physician. The purpose of this study is to assess disease manifestations of complement mediated thrombotic microangiopathy (TMA) and potential clinical predictors of disease manifestations and progression in patients with aHUS with or without eculizumab treatment in the clinical setting.</brief_summary>
	<brief_title>Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>1. Currently receiving eculizumab treatment in the M11001 aHUS Registry 2. Two normal platelet counts at least 4 weeks apart 3. Two normal LDH levels at least 4 weeks apart 4. Willing, committed, and able to return for ALL clinic visits and complete all studyrelated procedures 5. Patient or patient's parent/legal guardian must be willing and able to give written informed consent. Patient (if minor) must be willing to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees) 1. Any prior eculizumab treatment discontinuation 2. On chronic dialysis (defined as â‰¥3 months on dialysis) 3. Currently participating in another complement inhibitor trial 4. Life expectancy of &lt;6 months 5. Patient or patient's parent/legal guardian unable to give written informed consent. Patient (if minor) unable to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>